Novel approaches to drug design for the treatment of schizophrenia

Expert Opinion on Drug Discovery

Volumn 8, Issue 10, 2013, Pages 1285-1296

  Taly, Antoine ^a  

^a France   (France)

Author keywords

Allostery; G protein coupled receptors; Ligand gated ion channels; Schizophrenia; Structure based drug design

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; BLONANSERIN; CARPIPRAMINE; CHLORPROMAZINE; CLOCAPRAMINE; CLOFEKTON; CLOSPIPRAMINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; ILOPERIDONE; KETIPINOR; LIGAND GATED ION CHANNEL; LURASIDONE; OLANZAPINE; PALIPERIDONE; PEROSPIRONE; PRASINIL; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SERTINDOLE; SULPIRID; SULPIRIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XEROQUEL; ZICRONAPINE; ZIPRASIDONE; ZOTEPINE;

BRAIN; CONFORMATIONAL TRANSITION; DOPAMINERGIC SYSTEM; DRUG DESIGN; DRUG TARGETING; HUMAN; HUMAN BRAIN PROJECT; LIGAND BINDING; MENTAL DISEASE; NEUROPHARMACOLOGY; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN STRUCTURE; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; STRUCTURE ANALYSIS; STRUCTURE BASED DRUG DESIGN; X RAY CRYSTALLOGRAPHY;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; LIGAND-GATED ION CHANNELS; LIGANDS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; SCHIZOPHRENIA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84884607762     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.821108     Document Type: Review

References (100)

1. van Os J, Kapur S. Schizophrenia. Lancet 2009;374(9690):635-45
2. Marwaha S, Johnson S, Bebbington P, et al. Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. Br J Psychiatry 2007;191(1):30-7
3. Folsom DP, Hawthorne W, Lindamer L, et al. Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system. Am J Psychiatry 2005;162(2):370-6
4. van Os J, Kenis G, Rutten BPF. The environment and schizophrenia. Nature 2010;468(7321):203-12 . The non-genetic causes associated with schizophrenia.
5. Cardno AG, Marshall EJ, Coid B, et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry 1999;56(2):162
6. Weinberger DR, Berman KF, Suddath R, Torrey EF. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 1992;149(7):890-7
7. Arieti S. Interpretation of schizophrenia. Basic Books; New York: 1974
8. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009;8(1):41-54 .. Explains why allostery should be considered.
9. Lemoine D, Jiang R, Taly A, et al. Ligand-gated ion channels: new insights into neurological disorders and ligand recognition. Chem Rev 2012;112(12):6285-318 .. A complete overview of LGIC structure-function relationships.
10. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148(11):1474-86
11. Taly A, Corringer PJ, Guedin D, et al. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 2009;8(9):733-50 . Detailed explanation on allostery.
12. Vacic V, McCarthy S, Malhotra D, et al. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature 2011;471(7339):499-503
13. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1(3):179-86 . The classical dopaminergic hypothesis.
14. Snyder SH. Drugs and the brain. Scientific American Library/Scientific American Books Inc., New York; 1986
15. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
16. Nestler EJ, Hyman SE, Malenka RC. Molecular neuropharmacology: a foundation for clinical neuroscience. McGraw-Hill, Medical Pub. Division, New York; 2001
17. Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev 2005;29(6):1021-34
18. Leonard S, Mexal S, Freedman R. Smoking, genetics and schizophrenia: evidence for self medication. J Dual Diagn 2007;3(3-4):43-59
19. Prochaska JJ, Hall SM, Bero LA. Tobacco use among individuals with schizophrenia: what role has the tobacco industry played? Schizophr Bull 2008;34(3):555-67
20. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature 2010;468(7321):203-12
21. Martinotti G, Di Iorio G, Marini S, et al. Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review. J Biol Regul Homeost Agents 2012;26(3):347-56
22. de la Nuez Veulens A, Rodr?́guez RG. Protein-coupled receptors as targets for drug design. Biotecnol Apl 2009;26:24-33 .. Details how GPCR can be targeted with structure-based drug design.
23. Dromey JR, Pfleger KD. G protein coupled receptors as drug targets: the role of beta-arrestins. Endocr Metab Immune Disord Drug Targets 2008;8(1):51-61
24. Dupré DJ, Robitaille M, Rebois RV, Hébert TE. The role of Gbetagamma subunits in the organization, assembly, and function of GPCR signaling complexes. Annu Rev Pharmacol Toxicol 2009;49:31-56
25. Foord SM, Bonner TI, Neubig RR, et al. International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev 2005;57(2):279-88
26. Bockaert J, Pin J-P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J 1999;18(7):1723-9 . Structure-function of GPCRs.
27. Strange PG, Oligomers of D. 2 dopamine receptors. J Mol Neurosci 2005;26(2):155-60
28. Freissmuth M, Selzer E, Marullo S, et al. Expression of two human beta-adrenergic receptors in Escherichia coli: functional interaction with two forms of the stimulatory G protein. Proc Natl Acad Sci 1991;88(19):8548-52
29. Dalrymple MB, Pfleger KD, Eidne KA. G protein-coupled receptor dimers: functional consequences, disease states and drug targets. Pharmacol Ther 2008;118(3):359-71
30. Ginés S, Hillion J, Torvinen M, et al. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci 2000;97(15):8606-11
31. Fuxe K, Ferré S, Canals M, et al. Adenosine A 2A and dopamine D 2 heteromeric receptor complexes and their function. J Mol Neurosci 2005;26(2):209-20
32. Cabello N, Gand?́a J, Bertarelli DC, et al. Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J Neurochem 2009;109(5):1497-507
33. Fribourg M, Moreno JL, Holloway T, et al. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 2011;147(5):1011-23 . The role of heteromeric complexes in the effect of antipsychotic drugs.
34. Farde L, Nordstr€om AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49(7):538
35. Seeman P, Guan H-C, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia. 1993;365(6445):441-5
36. Lidow MS, Goldman-Rakic PS. A common action of clozapine, haloperidol, and remoxipride on D1-and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci 1994;91(10):4353-6
37. Lara DR, Dall'Igna OP, Ghisolfi ES, Brunstein MG. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(4):617-29
38. Deckert J, Brenner M, Durany N, et al. Up-regulation of striatal adenosine A2A receptors in schizophrenia. Neuroreport 2003;14(3):313-16
39. Yee BK, Singer P, Chen JF, et al. Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. Eur J Neurosci 2007;26(11):3237-52
40. Kafka SH, Corbett R. Selective adenosine A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia. Eur J Pharmacol 1996;295(2):147-54
41. Tsai S-J. Adenosine A2a receptor/dopamine D2 receptor heterooligomerization: a hypothesis that may explain behavioral sensitization to psychostimulants and schizophrenia. Med Hypotheses 2005;64(1):197-200
42. Lara DR, Souza DO. Schizophrenia: a purinergic hypothesis. Med Hypotheses 2000;54(2):157-66
43. Fujii Y, Shibata H, Kikuta R, et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 2003;13(2):71-6
44. Mart?́ SB, Cichon S, Propping P, N€othen M. Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am J Med Genet 2002;114(1):46-50
45. Devon RS, Anderson S, Teague PW, et al. The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol Psychiatry 2001;6(3):311
46. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998;281(5381):1349-52
47. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011;11(1):59-67
48. Pytliak M, Vargová V, Mech?́rová V, Fels?€oci M. Serotonin receptors-from molecular biology to clinical applications. Physiol Res 2011;60(1):15-25
49. González-Maeso J, Ang RL, Yuen T, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008;452(7183):93-7
50. Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003;26(1):25-40
51. Stevens KE, Wear KD. Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models. Pharmacol Biochem Behav 1997;57(4):869-74
52. Simosky JK, Stevens KE, Adler LE, Freedman R. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berl) 2003;165(4):386-96
53. Levin ED, Ellison GD, Salem C, et al. Behavioral effects of acute hexamethonium in rats chronically intoxicated with nicotine. Physiol Behav 1988;44(3):355-9
54. Dépatie L, O'Driscoll GA, Holahan AL, et al. Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 2002;27(6):1056-70
55. Rosse RB, Deutsch SI. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol 2002;25(5):272-5
56. Koike K, Hashimoto K, Takai N, et al. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res 2005;76(1):67
57. Martin LF, Freedman R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol 2007;78:225-46
58. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006;63(6):630
59. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008;165(8):1040-7
60. Leiser SC, Bowlby MR, Comery TA, Dunlop J. A cog in cognition: how the a7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther 2009;122(3):302-11
61. Lieberman J, Javitch J, Moore H. Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. Am J Psychiatry 2008;165(8):931-6
62. Seibt KJ, Oliveira Rda L, Rico EP, et al. Typical and atypical antipsychotics alter acetylcholinesterase activity and ache expression in zebrafish (Danio rerio) brain. Comp Biochem Physiol C Toxicol Pharmacol 2009;150(1):10-15
63. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006;26(4):363-82
64. Meador-Woodruff JH, Healy DJ. Glutamate receptor expression in schizophrenic brain. Brain Res Rev 2000;31(2):288-94
65. Kru?gel U, Kittner H, Illes P. Adenosine 5¢-triphosphate-induced dopamine release in the rat nucleus accumbens in vivo. Neurosci Lett 1999;265(1):49-52
66. Seibt KJ, Oliveira Rda L, Rico EP, et al. Antipsychotic drugs inhibit nucleotide hydrolysis in zebrafish (Danio rerio) brain membranes. Toxicol In Vitro 2009;23(1):78-82
67. Koizumi S, Ikeda M, Nakazawa K, et al. Inhibition by haloperidol of adenosine 5¢-triphosphate-evoked responses in rat pheochromocytoma cells. Biochem Biophys Res Commun 1995;210(2):624-30
68. Inoue K, Koizumi S, Ueno S. Implication of ATP receptors in brain functions. Prog Neurobiol 1996;50(5):483-92
69. Kittner H, Kru?gel U, Illes P. The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats. Neuroscience 2001;102(2):241-3
70. Motoyuki H, Gouaux E. Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature 2012;485(7397):207-12 . Structure of a P2X receptor.
71. Jiang R, Lemoine D, Martz A, et al. Agonist trapped in ATP-binding sites of the P2X2 receptor. Proc Natl Acad Sci 2011;108(22):9066-71
72. L€orinczi E ́ , Bhargava Y, Marino SF, et al. Involvement of the cysteine-rich head domain in activation and desensitization of the P2X1 receptor. Proc Natl Acad Sci 2012;109(28):11396-401
73. Changeux J-P, Taly A. Nicotinic receptors, allosteric proteins and medicine. Trends Mol Med 2008;14(3):93-102
74. Changeux J-P, Edelstein SJ. Allosteric mechanisms of signal transduction. Science 2005;308(5727):1424-8
75. Qiang C, Karplus M. Allostery and cooperativity revisited. Protein Sci 2009;17(8):1295-307
76. Taly A, Colas C, Malliavin T, et al. Discrimination of agonists versus antagonists of nicotinic ligands based on docking onto AChBP structures. J Mol Graph Model 2011;30:100-9
77. Lounnas V, Ritschel T, Kelder J, et al. Current progress in structure-based rational drug design marks a new mindset in drug discovery. Computat Struct Biotechnol J 2013;5(6):e201302011 . Description of structure-based drug design.
78. Shoichet BK, Kobilka BK. Structure-based drug screening for G-protein-coupled receptors. Trends Pharmacol Sci 2012;33(5):268-72 .. A demonstration of the feasibility of structure-based drug design on GPCR.
79. Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, a 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl) 1996;124(1):87-94
80. Gefvert O, Bergstr€om M, La°ngstr€om B, et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel-) in patients with schizophrenia. Psychopharmacology (Berl) 1998;135(2):119-26
81. Stephenson CM, Bigliani V, Jones HM, et al. Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo [123I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry 2000;177(5):408-15
82. Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 2002;956(2):349
83. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20(6):612-27
84. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441(3):137-40
85. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275(1):101-13
86. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009;23(1):65-73
87. Farde L, Nordstr€om AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49(7):538
88. Seeman P. Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 1992;7(4):261-84
89. Leysen JE, Janssen PM, Schotte A, et al. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT 2 receptors. Psychopharmacology (Berl) 1993;112:40-54
90. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124(1):57-73
91. Rupanwita G, Bhatia MS, Bhattacharya SK. Blonanserin in management of Schizophrenia. Delhi Psychiatry J 2012;15(2):406-11
92. Sumiyoshi T, Suzuki K, Sakamoto H, et al. Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy. Neuropsychopharmacology 1995;12(1):57-64
93. Setoguchi M, Sakamori M, Takehara S, Fukuda T. Effects of iminodibenzyl antipsychotic drugs on cerebral dopamine and a-adrenergic receptors. Eur J Pharmacol 1985;112(3):313-22
94. Yoshino T, Nisijima K, Shioda K, et al. Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex. Neurosci Lett 2004;364(1):16-21
95. Available from: www.ClinicalTrials.gov
96. Chien EY, Liu W, Zhao Q, et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010;330(6007):1091-5
97. Lomize MA, Lomize AL, Pogozheva ID, Mosberg HI. OPM: orientations of proteins in membranes database. Bioinformatics 2006;22(5):623-5
98. Jaakola VP, Griffith MT, Hanson MA, et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008;322(5905):1211-17 . Structure of an adenosine receptor.
99. Hibbs RE, Gouaux E. Principles of activation and permeation in an anion-selective Cys-loop receptor. Nature 2011;474(7349):54-60 . Structure of a pentameric LGIC.
100. Sobolevsky AI, Rosconi MP, Gouaux E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature 2009;462(7274):745-56 . Structure of a tetrameric LGIC.